Otonomy Inc. (NASDAQ: OTIC) is -2.35% lower on its value in year-to-date trading and has touched a low of $1.53 and a high of $4.39 in the current 52-week trading range. The OTIC stock was last observed hovering at around $3.74 in the last trading session, with the day’s gains setting it 0.44% off its average median price target of $9.00 for the next 12 months. It is also 62.0% off the consensus price target high of $11.00 offered by 5 analysts, but current levels are 47.75% higher than the price target low of $8.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $4.18, the stock is 14.05% and 15.99% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.13 million and changing 11.76% at the moment leaves the stock 42.75% off its SMA200. OTIC registered 67.71% gain for a year compared to 6-month gain of 3.31%. The firm has a 50-day simple moving average (SMA 50) of $3.7273 and a 200-day simple moving average (SMA200) of $2.9474.
The stock witnessed a -9.22% loss in the last 1 month and extending the period to 3 months gives it a 51.42%, and is 15.43% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.55% over the week and 8.05% over the month.
Otonomy Inc. (OTIC) has around 49 employees, a market worth around $181.99M and $0.40M in sales. Distance from 52-week low is 173.20% and -4.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-81.00%).
Otonomy Inc. (OTIC) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Otonomy Inc. (OTIC) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Otonomy Inc. is expected to release its quarterly report on 11/10/2020 and quarterly earnings per share for the current quarter are estimated at -$0.24 with sales reaching $50k over the same period.The EPS is expected to grow by 11.60% this year, but quarterly earnings will post 20.00% year-over-year. Quarterly sales are estimated to shrink -60.00% in year-over-year returns.
Otonomy Inc. (OTIC) Top Institutional Holders
55 institutions hold shares in Otonomy Inc. (OTIC), with 170.24k shares held by insiders accounting for 0.35% while institutional investors hold 63.67% of the company’s shares. The shares outstanding are 48.23M, and float is at 45.61M with Short Float at 0.63%. Institutions hold 63.45% of the Float.
The top institutional shareholder in the company is Tpg Group Holdings (sbs) Advisors, Inc. with over 2.16 million shares valued at $7.82 million. The investor’s holdings represent 4.48% of the OTIC Shares outstanding. As of Jun 29, 2020, the second largest holder is Renaissance Technologies, LLC with 1.85 million shares valued at $6.7 million to account for 3.84% of the shares outstanding. The other top investors are Sofinnova Investments, Inc. which holds 1.65 million shares representing 3.42% and valued at over $5.98 million, while Vanguard Group, Inc. (The) holds 2.92% of the shares totaling 1.41 million with a market value of $5.09 million.
Otonomy Inc. (OTIC) Insider Activity
A total of 0 insider transactions have happened at Otonomy Inc. (OTIC) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Otonomy Inc. (OTIC): Who are the competitors?
The company’s main competitors (and peers) include Applied Genetic Technologies Corporation (AGTC) that is trading 90.58% up over the past 12 months. Akebia Therapeutics Inc. (AKBA) is 126.81% up on the 1-year trading charts. Short interest in the company’s stock has risen 37.55% from the last report on Jun 29, 2020 to stand at a total of 0.18 million short shares sold with a short interest ratio of 0.43.